PP127-MON: The Need for a Special Diet for Elderly Patients with Dysphagia von Melgaard, D, Eg Nefer, T, Rasmussen, A, Liisberg, A, Grønlund, B

Volltext

0268: Topoisomerase I (Top1) Amplifications and Deletions As a Predective Marker for Chemotherapy with Topotecan in Women with Advanced Ovarian Cancer (Oc) von Spahn-Horn, S., Ejlertsen, B., Engelholm, S. A., GrØNlund, B., Petersen, B. Laub, Nedergaard, L., Nielsen, K. V., Poulsen, T.

Volltext

Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel–platinum von Gronlund, B., Lundvall, L., Christensen, I.J., Knudsen, J.B., Høgdall, C.

Volltext

Serious intestinal complication five years after insertion of a Nova-T von Grønlund, B., Blaabjerg, J.

Volltext

Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma : value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125) von GRONLUND, B, HØGDALL, E. V. S, CHRISTENSEN, I. J, JOHANSEN, J. S, NØRGAARD-PEDERSEN, B, ENGELHOLM, S. A, HØGDALL, C

Volltext

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? von GRONLUND, B, HANSEN, H. H, HØGDALL, C, HOGDALL, E. V. S, ENGELHOLM, S. A

Volltext

Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma von GRONLUND, B., DEHN, H., HØGdall, C.K., ENGELHOLM, S.A., JØRGENSEN, M., NØRGAARD‐PEDERSEN, B., HØGDALL, E.V.S.

Volltext

Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma? von GRONLUND, Bo, HØGDALL, Claus, HILDEN, Jørgen, ENGELHOLM, Svend A, HØGDALL, Estrid V. S, HANSEN, Heine H

Volltext

Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma von GRONLUND, B., DEHN, H., HØGdall, C. K., ENGELHOLM, S. A., JØRGENSEN, M., NØRGAARD-PEDERSEN, B., HØGDALL, E. V.S.

Volltext

Management of Endoscopic Impaction during Routine ERCP Using “the Gastric Grip” von Grønlund, B., Svendsen, L. B.

Volltext

Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies von Aguinam, Ernest T., Nadesalingam, Angalee, Chan, Andrew, Smith, Peter, Paloniemi, Minna, Cantoni, Diego, Gronlund, Jessica, Gronlund, Helen, Carnell, George W., Castillo-Olivares, Javier, Temperton, Nigel, Blacklaws, Barbara, Heeney, Jonathan L., Baxendale, Helen

Volltext

SHOULD CA125 RESPONSE CRITERIA BE PREFERRED TO WHO CRITERIA IN THE MONITORING OF SECOND-LINE CHEMOTHERAPY (SLC) OF EPITHELIAL OVARIAN CARCINOMA (EOC)? von Gronlund, B., Hansen, H. H., Engelholm, S. A., Hogdall, E. V.S., Hogdall, C.

Volltext

Clinical evaluation of a prototype glucose electrode von Grønlund, Bo, Grønlund, Lars, Madsbad, Sten, Fogh-Andersen, Niels

Volltext

Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma von Gronlund, Bo, Høgdall, Claus, Hansen, Heine H., Engelholm, Svend A.

Volltext

Results of Reinduction Therapy with Paclitaxel and Carboplatin in Recurrent Epithelial Ovarian Cancer von Gronlund, Bo, Høgdall, Claus, Hansen, Heine H., Engelholm, Svend A.

Volltext

Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane : Results from a multicenter phase I/II study von GRONLUND, Bo, ENGELHOLM, Svend A, HORVATH, Gyorgy, MÄENPÄÄ, Johanna, RIDDERHEIM, Mona

Volltext

Efficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma von Gronlund, Bo, Hansen, Heine H., Høgdall, Claus, Engelholm, Svend A.

Volltext

Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel–Platinum? von Gronlund, Bo, Høgdall, Claus, Christensen, Ib J, Engelholm, Svend A, Hansen, Heine H

Volltext

Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125) von Gronlund, B., Hgdall, E.V.S., Christensen, I.J., Johansen, J.S., Norgaard-Pedersen, B., Engelholm, S.A., Hogdall, C.

Volltext

Recurrent epithelial ovarian cancer: Validation and improvement of an established prognostic index von Gronlund, Bo, Christensen, Ib J., Bülow-Lehnsby, Anne Lene, Engelholm, Svend A., Hansen, Heine H., Høgdall, Claus

Volltext